Research programme: HCV therapies - elbion NV/Gilead

Drug Profile

Research programme: HCV therapies - elbion NV/Gilead

Latest Information Update: 15 Mar 2010

Price : $50

At a glance

  • Originator elbion NV
  • Developer Gilead Sciences
  • Class Heterocyclic compounds
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 23 Aug 2007 Preclinical development is ongoing
  • 05 Dec 2006 4AZA Bioscience has merged with elbion to form elbion NV
  • 24 Jan 2006 Preclinical trials in Hepatitis C treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top